|
| | 101ST GENERAL ASSEMBLY
State of Illinois
2019 and 2020
HB4771 Introduced , by Rep. Deanne M. Mazzochi SYNOPSIS AS INTRODUCED:
|
| |
Amends the Illinois Food, Drug and Cosmetic Act. Requires a manufacturer of a prescription drug that is sold, offered for sale, or distributed in this State, or placed on a formulary to be eligible for payment, co-payment, or reimbursement in this State, to notify the Department of Public Health of specified information concerning active pharmaceutical ingredients.
| |
| | |
| | A BILL FOR |
|
|
| | HB4771 | | LRB101 17711 CPF 69458 b |
|
|
| 1 | | AN ACT concerning health.
|
| 2 | | Be it enacted by the People of the State of Illinois,
|
| 3 | | represented in the General Assembly:
|
| 4 | | Section 5. The Illinois Food, Drug and Cosmetic Act is |
| 5 | | amended by adding Section 3.24 as follows:
|
| 6 | | (410 ILCS 620/3.24 new) |
| 7 | | Sec. 3.24. Active pharmaceutical ingredients. A |
| 8 | | manufacturer of a prescription drug that is sold, offered for |
| 9 | | sale, or distributed in this State, or placed on a formulary to |
| 10 | | be eligible for payment, co-payment, or reimbursement in this |
| 11 | | State, must notify the Department of Public Health of the |
| 12 | | following: |
| 13 | | (1) the country of origin for the active pharmaceutical |
| 14 | | ingredient, in a searchable form by proprietary name, such |
| 15 | | as a brand name, if one is associated with the drug |
| 16 | | product, and ingredient name, such as a generic chemical |
| 17 | | name; if the country of origin for a manufacturer varies |
| 18 | | based on dosage or route of administration, each country of |
| 19 | | origin shall be specified for each such dosage or route of |
| 20 | | administration; |
| 21 | | (2) the Drug Master File number for any angiotensin II |
| 22 | | receptor blocker and certification that the active |
| 23 | | ingredient specification contains a nitrosamine |